top of page
ribbon hero nice web.jpg

Our Science

Antibody Delivery
Small Molecule Delivery and siRNA Delivery
Protein Delivery and Peptide Delivery
Limited Systemic Clearance and Limited Systemic Toxicity
triple ribbon hero 1.jpg

Delivering medicine to specific tissues—and ensuring it stays there—is a significant challenge due to natural barriers and clearance mechanisms. These obstacles hinder effective drug delivery and retention, such as mucociliary clearance in the lungs, rapid transit and enzymatic breakdown in the GI tract, and the blood-brain barrier in the CNS.

triple ribbon hero 1.jpg

Delivering medicine to specific tissues—and ensuring it stays there—is a significant challenge due to natural barriers and clearance mechanisms. These obstacles hinder effective drug delivery and retention, such as mucociliary clearance in the lungs, rapid transit and enzymatic breakdown in the GI tract, and the blood-brain barrier in the CNS.

Our delivery technologies – paints – are based on tissue endogenous surfactant peptides. Our Paints include PulmoPaint™ for delivery to the lungs, CerebroPaint™ for the brain and CNS, and GastroPaint™ for the GI tract. Paint precisely delivers medicines to distinct tissues for controlled release at the site of disease.

painting skin hero web.jpg
painting skin hero web.jpg

Our delivery technologies – paints – are based on tissue endogenous surfactant peptides. Our Paints include PulmoPaint™ for delivery to the lungs, CerebroPaint™ for the brain and CNS, and GastroPaint™ for the GI tract. Paint precisely delivers medicines to distinct tissues for controlled release at the site of disease.

Our paints enable long-acting and controlled release at the site of disease. In combination with warheads with potent biological activity, we have identified drug candidates across disease indications. We continue to advance these candidates to provide long-lasting efficacy in the lung, the brain and CNS, and GI tract.

Untitled.png
Undisclosed
GastroPaint™
Untitled.png
Undisclosed
CerebroPaint™
Untitled.png
Oncology
PulmoPaint™
Untitled.png
A1AT
PulmoPaint™

Indication

Discovery

Pre-clinical

IND-Enabling

Status

Undisclosed

Untitled.png
GastroPaint™

Undisclosed

Untitled.png
CerebroPaint™
PulmoPaint™

A1AT

Untitled.png

Oncology

Untitled.png

Indication

Discovery

Pre-clinical

IND-Enabling

Status

Our paints enable long-acting and controlled release at the site of disease. In combination with warheads with potent biological activity, we have identified drug candidates across disease indications. We continue to advance these candidates to provide long-lasting efficacy in the lung, the brain and CNS, and GI tract.

Pipeline

June 1, 2010

A human surfactant peptide-elastase inhibitor construct as a treatment for emphysema

Two million Americans suffer from pulmonary emphysema, costing $2.5 billion/year and contributing to 100,000 deaths/year.

Publications

footer.jpg
bottom of page